Post-ASH, Onyx Has Grand Plans for Carfilzomib And Nexavar
This article was originally published in The Pink Sheet Daily
Executive Summary
Following a buoyant meeting at ASH, Onyx outlines its next steps as it strives to move from being a "one-product" company, to filing an NDA for a second cancer drug by mid-2011.